Albert Labs Announces a Distinguished Clinical and Scientific Advisory Board Post published:June 24, 2021 Post category:Press Release
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer Post published:June 24, 2021 Post category:Press Release
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board Post published:June 24, 2021 Post category:Press Release
Exclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange Post published:June 24, 2021 Post category:Press Release
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species Post published:June 24, 2021 Post category:Press Release
Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family Post published:June 24, 2021 Post category:Press Release
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004 Post published:June 24, 2021 Post category:Press Release
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board Post published:June 23, 2021 Post category:Press Release
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues Post published:June 23, 2021 Post category:Press Release
Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’ Post published:June 23, 2021 Post category:Press Release